When I last wrote on Salix Pharmaceuticals (SLXP) in the fall of 2012, I thought the shares of this specialty pharmaceutical company held solid potential for those investors who could accept the risks that went with the story. Since then, the shares are up about 60% - a pretty solid return even when considering the bull market in healthcare names.
I don't believe that these shares have hit their ceiling yet. Management has shown its ability to identify, develop, and/or acquire promising products in the gastrointestinal field. Investors can also look forward to upcoming data on Xifaxan in the treatment of IBS-D and an FDA panel meeting tied to the company's appeal of a complete response letter...
Only subscribers can access this article, which is part of the PRO research library covering 3,801 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: